GlycoMimetics (GLYC) | Financial Analysis & Statements
GlycoMimetics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
0
Operating Income
-2.4M
Net Income
-2.3M
EPS (Diluted)
$-0.04
Balance Sheet Metrics
Total Assets
6.0M
Total Liabilities
2.6M
Shareholders Equity
3.4M
Debt to Equity
0.78
Cash Flow Metrics
Operating Cash Flow
-2.2M
Free Cash Flow
-5.1M
Revenue & Profitability Trend
GlycoMimetics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 10.0K | 75.0K | 1.2M | 10.2M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 14.3M | 20.1M | 28.4M | 47.5M | 44.9M |
| Selling, General & Administrative | 18.2M | 19.2M | 19.1M | 17.1M | 16.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 32.5M | 39.3M | 47.5M | 64.6M | 61.7M |
| Operating Income | -32.5M | -39.3M | -47.4M | -63.4M | -51.5M |
| Operating Margin % | 0.0% | -392,746.6% | -63,203.8% | -5,470.7% | -506.8% |
| Non-Operating Items | |||||
| Interest Income | 935.3K | 2.4M | 714.5K | 19.8K | 482.5K |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -6.3M | - | - | - | - |
| Pre-tax Income | -37.9M | -36.9M | -46.7M | -63.4M | -51.0M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -37.9M | -36.9M | -46.7M | -63.4M | -51.0M |
| Net Margin % | 0.0% | -368,987.8% | -62,251.1% | -5,469.0% | -502.1% |
| Key Metrics | |||||
| EBITDA | -26.2M | -39.1M | -47.2M | -63.2M | -51.2M |
| EPS (Basic) | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 |
| EPS (Diluted) | $-0.59 | $-0.58 | $-0.89 | $-1.23 | $-1.12 |
| Basic Shares Outstanding | 64477249 | 63342465 | 52531173 | 51453294 | 45721139 |
| Diluted Shares Outstanding | 64477249 | 63342465 | 52531173 | 51453294 | 45721139 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
GlycoMimetics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 10.7M | 41.8M | 47.9M | 90.3M | 137.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 11.1M | 43.8M | 50.7M | 90.8M | 138.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | - | 767.8K | 751.2K | 3.0M | 3.8M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | 154.2K | 294.7K | - | - |
| Total Non-Current Assets | 0 | 1.5M | 1.1M | 3.6M | 4.6M |
| Total Assets | 11.1M | 45.3M | 51.8M | 94.3M | 142.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.4M | 868.1K | 970.2K | 2.1M | 2.1M |
| Short-term Debt | 66.8K | 741.6K | 918.6K | 1.0M | 898.5K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 5.8M | 6.8M | 8.9M | 11.8M | 12.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 66.8K | 0 | 918.6K | 1.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 66.8K | 0 | 918.6K | 2.2M |
| Total Liabilities | 5.8M | 6.9M | 8.9M | 12.7M | 14.6M |
| Equity | |||||
| Common Stock | 64.5K | 64.4K | 54.4K | 52.3K | 49.0K |
| Retained Earnings | -494.4M | -456.5M | -419.6M | -372.9M | -309.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.3M | 38.4M | 42.9M | 81.6M | 128.2M |
| Key Metrics | |||||
| Total Debt | 66.8K | 808.4K | 918.6K | 1.9M | 2.8M |
| Working Capital | 5.3M | 37.0M | 41.8M | 79.0M | 125.8M |
Balance Sheet Composition
GlycoMimetics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -37.9M | -36.9M | -46.7M | -63.4M | -51.0M |
| Depreciation & Amortization | 35.2K | 153.3K | 207.1K | 264.6K | 270.8K |
| Stock-Based Compensation | 4.8M | 3.6M | 3.9M | 6.1M | 6.9M |
| Working Capital Changes | -1.3M | -1.1M | -2.1M | -880.9K | 114.5K |
| Operating Cash Flow | -33.9M | -33.4M | -43.9M | -57.2M | -43.1M |
| Investing Activities | |||||
| Capital Expenditures | 20.0K | -21.4K | -84.2K | -14.9K | -68.5K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 20.0K | -21.4K | -84.2K | -14.9K | -68.5K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 0 | 28.7M | 4.2M | 10.7M | 17.8M |
| Free Cash Flow | -31.1M | -34.9M | -46.5M | -57.5M | -39.3M |
| Net Change in Cash | -33.9M | -4.7M | -39.9M | -46.5M | -25.3M |
Cash Flow Trend
GlycoMimetics Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-32.85
Forward P/E
-1.74
Price to Book
370.47
PEG Ratio
0.43
Profitability Ratios
Return on Equity
-712.88%
Return on Assets
-341.52%
Financial Health
Current Ratio
2.29
Debt to Equity
0.00
Per Share Data
EPS (TTM)
$-0.59
Book Value per Share
$0.05
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GLYC | 1.2B | -32.85 | 370.47 | -712.88% | 0.00% | 0.00 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






